Abstract:Drug-induced torsade de pointes (TdP) is a life-threatening ventricular arrhythmia responsible for the withdrawal of many drugs from the market. Although currently used TdP risk-assessment methods are effective, they are expensive and prone to produce false positives. In recent years, in silico cardiac simulations have proven to be a valuable tool for the prediction of drug effects. The objective of this work is to evaluate different biomarkers of drug-induced proarrhythmic risk and to develop an in silico risk classifier. Cellular simulations were performed using a modified version of the O'Hara et al. ventricular action potential model and existing pharmacological data (IC50 and effective free therapeutic plasma concentration, EFTPC) for 109 drugs of known torsadogenic risk (51 positive). For each compound, four biomarkers were tested: Tx (drug concentration leading to a 10% prolongation of the action potential over the EFTPC), TqNet (net charge carried by ionic currents when exposed to 10 times the EFTPC with respect to the net charge in control), Ttriang (triangulation for a drug concentration of 10 times the EFTPC over triangulation in control), and TEAD (drug concentration originating early afterdepolarizations over EFTPC). Receiver operating characteristic (ROC) curves were built for each biomarker to evaluate their individual predictive quality. At the optimal cutoff point, accuracies for Tx, TqNet, Ttriang, and TEAD were 89.9, 91.7, 90.8, and 78.9% respectively. The resulting accuracy of the hERG IC50 test (current biomarker) was 78.9%. When combining Tx, TqNet and Ttriang into a classifier based on decision trees, the prediction improves, achieving an accuracy of 94.5%. The sensitivity analysis revealed that most of the effects on the action potential are mainly due to changes in IKr, ICaL, INaL and IKs. In fact, considering that drugs affect only these four currents, TdP risk classification can be as accurate as when considering effects on the seven main currents proposed by the CiPA initiative. Finally, we built a ready-to-use tool (based on more than 450 000 simulations), which can be used to quickly assess the proarrhythmic risk of a compound. In conclusion, our in silico tool can be useful for the preclinical assessment of TdP-risk and to reduce costs related with new drug development. The TdP risk-assessment tool and the software used in this work are available at <a class="extLink" href="https://riunet.upv.es/handle/10251/136919">https://riunet.upv.es/handle/10251/136919</a>.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c00201?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c00201</a>.Equations of the activation (mss) and inactivation gates (hss, hssp, and jss) at the steady state of the rapid Na+ current in the O'Hara et al. model and in the modified version. IC50 values (nM), Hill coefficients, and effective free therapeutic plasma concentration (EFTPC) (nM) used to simulated the 109 drugs studied in this work. Performance of the four arrhythmogenic biomarkers depending on the currents on which the effect of the drug is assumed: the seven CiPA currents; IKr, ICaL, and IKs, or, IKr, ICaL, and INaL. Performance of the classifiers depending on the biomarkers used as inputs. Results of the sensitivity analysis with the multiple linear regression method. Results of the sensitivity analysis applying the PLS method. Decision trees that constitute the binary TdP risk classifier based on Tx, TqNet, and Ttriang (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c00201/suppl_file/ci0c00201_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Drug‐induced torsades de pointes and implications for drug development

Drug-induced proarrhythmia: Discussion and considerations for clinical practice

Development of Therapeutics for Heart Failure

Drug-induced QT interval prolongation and torsades de pointes

Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system

Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes

Independent derivations of the axis of arrhythmia for predicting drug-induced torsades de pointes

Drug-induced long QT syndrome: Concept and non-clinical models for predicting the onset of drug-induced torsade de pointes in patients in compliance with ICH E14/S7B guidance

Torsade de pointes: mechanisms and management

Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes

An Updated Safety Review of the Relationship Between Atypical Antipsychotic Drugs, the QTc Interval and Torsades de Pointe As: Implications for Clinical Use

Prevention of Torsade de Pointes in Hospital Settings

Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models.

In Silico Classifiers for the Assessment of Drug Proarrhythmicity

Preclinical Assessment of Drug-Induced Proarrhythmias: Role of the Arterially Perfused Rabbit Left Ventricular Wedge Preparation

Modulation of the Late Sodium Current by ATX-II and Ranolazine Affects the Reverse Use-Dependence and Proarrhythmic Liability of IKrblockade

Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias.

A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes

Torsade de pointes

Discarding the Baby with the Bathwater

Exploring the hidden danger of noncardiac drugs.